ANGN

Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Angion Biomedica: Interesting New IPO With Late Stage Asset Targeting A Novel Indication

Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated Pneumonia

Angion Announces Partial Waiver of Certain Lock-up Restrictions

ANGN Stock Price Increases Over 25% Pre-Market: Why It Happened